Refine
Year of publication
- 2020 (142) (remove)
Has Fulltext
- yes (142)
Is part of the Bibliography
- no (142)
Keywords
- Hadron-Hadron scattering (experiments) (6)
- Heavy Ion Experiments (4)
- Heavy-ion collision (3)
- Biomarkers (2)
- Depression (2)
- Particle and resonance production (2)
- portal hypertension (2)
- 19F (1)
- ACLF (1)
- ADGRE1 (1)
Institute
- Physik (115)
- Frankfurt Institute for Advanced Studies (FIAS) (99)
- Informatik (93)
- Medizin (18)
- Biochemie und Chemie (2)
- Psychologie (2)
- Biochemie, Chemie und Pharmazie (1)
- Biowissenschaften (1)
- Deutsches Institut für Internationale Pädagogische Forschung (DIPF) (1)
- ELEMENTS (1)
- Geowissenschaften (1)
- Senckenbergische Naturforschende Gesellschaft (1)
- Wirtschaftswissenschaften (1)
- Zentrum für Biomolekulare Magnetische Resonanz (BMRZ) (1)
The transcription factor ∆Np63 is a master regulator of epithelial cell identity and essential for the survival of squamous cell carcinoma (SCC) of lung, head and neck, oesophagus, cervix and skin. Here, we report that the deubiquitylase USP28 stabilizes ∆Np63 and maintains elevated ∆NP63 levels in SCC by counteracting its proteasome‐mediated degradation. Impaired USP28 activity, either genetically or pharmacologically, abrogates the transcriptional identity and suppresses growth and survival of human SCC cells. CRISPR/Cas9‐engineered in vivo mouse models establish that endogenous USP28 is strictly required for both induction and maintenance of lung SCC. Our data strongly suggest that targeting ∆Np63 abundance via inhibition of USP28 is a promising strategy for the treatment of SCC tumours.
Introduction: Esophageal atresia with or without tracheoesophageal fistula (EA/TEF) occurs approximately 1 in 3.500 live births representing the most common malformation of the upper digestive tract. Only half a century ago, EA/TEF was fatal among affected newborns suggesting that the steady birth prevalence might in parts be due to mutational de novo events in genes involved in foregut development.
Methods: To identify mutational de novo events in EA/TEF patients, we surveyed the exome of 30 case-parent trios. Identified and confirmed de novo variants were prioritized using in silico prediction tools. To investigate the embryonic role of genes harboring prioritized de novo variants we performed targeted analysis of mouse transcriptome data of esophageal tissue obtained at the embryonic day (E) E8.5, E12.5, and postnatal.
Results: In total we prioritized 14 novel de novo variants in 14 different genes (APOL2, EEF1D, CHD7, FANCB, GGT6, KIAA0556, NFX1, NPR2, PIGC, SLC5A2, TANC2, TRPS1, UBA3, and ZFHX3) and eight rare de novo variants in eight additional genes (CELSR1, CLP1, GPR133, HPS3, MTA3, PLEC, STAB1, and PPIP5K2). Through personal communication during the project, we identified an additional EA/TEF case-parent trio with a rare de novo variant in ZFHX3. In silico prediction analysis of the identified variants and comparative analysis of mouse transcriptome data of esophageal tissue obtained at E8.5, E12.5, and postnatal prioritized CHD7, TRPS1, and ZFHX3 as EA/TEF candidate genes. Re-sequencing of ZFHX3 in additional 192 EA/TEF patients did not identify further putative EA/TEF-associated variants.
Conclusion: Our study suggests that rare mutational de novo events in genes involved in foregut development contribute to the development of EA/TEF.